Anti-a-enolase is a prognostic marker in postoperative lung cancer patients

Kuan Chung Hsiao, Neng Yao Shih, Pei Yi Chu, Yi Mei Hung, Jia Yi Liao, Shao Wen Chou, Yi Yuan Yang, Gee Chen Chang, Ko Jiunn Liu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Our previous studies suggest that antibodies against ENO1 (anti-ENO1 Ab) have a protective role in patients with non-small cell lung carcinoma. In this study, we evaluated the prognostic value of anti-ENO1 Ab levels in non-small cell lung carcinoma patients undergoing surgery. Circulating levels of anti-ENO1 Ab were assessed in 85 non-small cell lung carcinoma patients before and after surgery, and were correlated with clinical outcome. After surgery, patients with a higher increase of anti-ENO1 Ab had a lower hazard ratio and a better progression-free survival. Using animal models, we demonstrated that tumor cells reduce the circulating levels of anti-ENO1 Ab through physical absorption and neutralization of anti-ENO1 Ab with surface-expressed and secreted ENO1, respectively. Mice transplanted with ENO1-overexpressing tumors generated ENO1-specific regulatory T cells to suppress the production of anti-ENO1 Ab. Our results suggest that the increase of anti-ENO1 Ab may reflect anti-tumor immune responses and serve as a prognostic marker in postoperative lung cancer patients.

Original languageEnglish
Pages (from-to)35073-35086
Number of pages14
JournalOncotarget
Volume6
Issue number33
DOIs
Publication statusPublished - 2015

Fingerprint

Phosphopyruvate Hydratase
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Circulating Neoplastic Cells
Regulatory T-Lymphocytes
Disease-Free Survival
Neoplasms
Animal Models
Antibodies

Keywords

  • ENO1
  • Lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Hsiao, K. C., Shih, N. Y., Chu, P. Y., Hung, Y. M., Liao, J. Y., Chou, S. W., ... Liu, K. J. (2015). Anti-a-enolase is a prognostic marker in postoperative lung cancer patients. Oncotarget, 6(33), 35073-35086. https://doi.org/10.18632/oncotarget.5316

Anti-a-enolase is a prognostic marker in postoperative lung cancer patients. / Hsiao, Kuan Chung; Shih, Neng Yao; Chu, Pei Yi; Hung, Yi Mei; Liao, Jia Yi; Chou, Shao Wen; Yang, Yi Yuan; Chang, Gee Chen; Liu, Ko Jiunn.

In: Oncotarget, Vol. 6, No. 33, 2015, p. 35073-35086.

Research output: Contribution to journalArticle

Hsiao, KC, Shih, NY, Chu, PY, Hung, YM, Liao, JY, Chou, SW, Yang, YY, Chang, GC & Liu, KJ 2015, 'Anti-a-enolase is a prognostic marker in postoperative lung cancer patients', Oncotarget, vol. 6, no. 33, pp. 35073-35086. https://doi.org/10.18632/oncotarget.5316
Hsiao KC, Shih NY, Chu PY, Hung YM, Liao JY, Chou SW et al. Anti-a-enolase is a prognostic marker in postoperative lung cancer patients. Oncotarget. 2015;6(33):35073-35086. https://doi.org/10.18632/oncotarget.5316
Hsiao, Kuan Chung ; Shih, Neng Yao ; Chu, Pei Yi ; Hung, Yi Mei ; Liao, Jia Yi ; Chou, Shao Wen ; Yang, Yi Yuan ; Chang, Gee Chen ; Liu, Ko Jiunn. / Anti-a-enolase is a prognostic marker in postoperative lung cancer patients. In: Oncotarget. 2015 ; Vol. 6, No. 33. pp. 35073-35086.
@article{e3e02e5c8c6245339b5abc716052fcd2,
title = "Anti-a-enolase is a prognostic marker in postoperative lung cancer patients",
abstract = "Our previous studies suggest that antibodies against ENO1 (anti-ENO1 Ab) have a protective role in patients with non-small cell lung carcinoma. In this study, we evaluated the prognostic value of anti-ENO1 Ab levels in non-small cell lung carcinoma patients undergoing surgery. Circulating levels of anti-ENO1 Ab were assessed in 85 non-small cell lung carcinoma patients before and after surgery, and were correlated with clinical outcome. After surgery, patients with a higher increase of anti-ENO1 Ab had a lower hazard ratio and a better progression-free survival. Using animal models, we demonstrated that tumor cells reduce the circulating levels of anti-ENO1 Ab through physical absorption and neutralization of anti-ENO1 Ab with surface-expressed and secreted ENO1, respectively. Mice transplanted with ENO1-overexpressing tumors generated ENO1-specific regulatory T cells to suppress the production of anti-ENO1 Ab. Our results suggest that the increase of anti-ENO1 Ab may reflect anti-tumor immune responses and serve as a prognostic marker in postoperative lung cancer patients.",
keywords = "ENO1, Lung cancer",
author = "Hsiao, {Kuan Chung} and Shih, {Neng Yao} and Chu, {Pei Yi} and Hung, {Yi Mei} and Liao, {Jia Yi} and Chou, {Shao Wen} and Yang, {Yi Yuan} and Chang, {Gee Chen} and Liu, {Ko Jiunn}",
year = "2015",
doi = "10.18632/oncotarget.5316",
language = "English",
volume = "6",
pages = "35073--35086",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "33",

}

TY - JOUR

T1 - Anti-a-enolase is a prognostic marker in postoperative lung cancer patients

AU - Hsiao, Kuan Chung

AU - Shih, Neng Yao

AU - Chu, Pei Yi

AU - Hung, Yi Mei

AU - Liao, Jia Yi

AU - Chou, Shao Wen

AU - Yang, Yi Yuan

AU - Chang, Gee Chen

AU - Liu, Ko Jiunn

PY - 2015

Y1 - 2015

N2 - Our previous studies suggest that antibodies against ENO1 (anti-ENO1 Ab) have a protective role in patients with non-small cell lung carcinoma. In this study, we evaluated the prognostic value of anti-ENO1 Ab levels in non-small cell lung carcinoma patients undergoing surgery. Circulating levels of anti-ENO1 Ab were assessed in 85 non-small cell lung carcinoma patients before and after surgery, and were correlated with clinical outcome. After surgery, patients with a higher increase of anti-ENO1 Ab had a lower hazard ratio and a better progression-free survival. Using animal models, we demonstrated that tumor cells reduce the circulating levels of anti-ENO1 Ab through physical absorption and neutralization of anti-ENO1 Ab with surface-expressed and secreted ENO1, respectively. Mice transplanted with ENO1-overexpressing tumors generated ENO1-specific regulatory T cells to suppress the production of anti-ENO1 Ab. Our results suggest that the increase of anti-ENO1 Ab may reflect anti-tumor immune responses and serve as a prognostic marker in postoperative lung cancer patients.

AB - Our previous studies suggest that antibodies against ENO1 (anti-ENO1 Ab) have a protective role in patients with non-small cell lung carcinoma. In this study, we evaluated the prognostic value of anti-ENO1 Ab levels in non-small cell lung carcinoma patients undergoing surgery. Circulating levels of anti-ENO1 Ab were assessed in 85 non-small cell lung carcinoma patients before and after surgery, and were correlated with clinical outcome. After surgery, patients with a higher increase of anti-ENO1 Ab had a lower hazard ratio and a better progression-free survival. Using animal models, we demonstrated that tumor cells reduce the circulating levels of anti-ENO1 Ab through physical absorption and neutralization of anti-ENO1 Ab with surface-expressed and secreted ENO1, respectively. Mice transplanted with ENO1-overexpressing tumors generated ENO1-specific regulatory T cells to suppress the production of anti-ENO1 Ab. Our results suggest that the increase of anti-ENO1 Ab may reflect anti-tumor immune responses and serve as a prognostic marker in postoperative lung cancer patients.

KW - ENO1

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84946568787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946568787&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5316

DO - 10.18632/oncotarget.5316

M3 - Article

VL - 6

SP - 35073

EP - 35086

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 33

ER -